The company’s next generation barrier technology is designed to support stability, efficiency, and sustainability goals. PARIS, Dec. 16, 2025 /PRNewswire/ — LOGThe company’s next generation barrier technology is designed to support stability, efficiency, and sustainability goals. PARIS, Dec. 16, 2025 /PRNewswire/ — LOG

LOG to Present Eco Sustainable Barrier Packaging at Pharmapack Europe 2026

2025/12/16 21:15
2 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

The company’s next generation barrier technology is designed to support stability, efficiency, and sustainability goals.

PARIS, Dec. 16, 2025 /PRNewswire/ — LOG Pharma Primary Packaging will showcase its advanced sustainable pharmaceutical packaging solutions at Pharmapack Europe 2026, held January 21 to 22 in Paris, France.

The company will exhibit at Hall 4, Stand B28, its Eco barrier together with LOG’s full range of primary medicine packaging solutions. Eco has also been selected for the Pharmapack Product Spotlight Gallery, a dedicated space that highlights innovative solutions shaping the future of the industry.

Eco combines high performance with responsible material use. Powered by Dow HEALTH+ pharma grade resins, Eco was designed for manufacturers that want reliable moisture and oxygen protection in a lighter, more resource efficient container. The bottle structure supports up to 30 percent weight reduction compared to first  standard bottles while maintaining strong barrier performance. This supports a lower environmental footprint without affecting the protection needed for sensitive formulations.

Eco’s optimized multilayer structure can reduce bottle costs by more than 50%, helping pharmaceutical companies simplify stability planning, reduce reliance on desiccants or oxygen scavengers, and speed up formulation development.

“Eco represents our commitment to practical sustainability,” said Noam Nahari, VP Marketing and Business Development at LOG Pharma. “It gives pharmaceutical companies the protection they expect while helping them reduce material use and overall environmental impact. Pharmapack Europe is the right place to show what this technology can achieve.”

Pharmaceutical packaging must address the growing challenge of active pharmaceutical ingredients that are sensitive to moisture and oxygen. LOG data shows that up to 90% of APIs are moisture sensitive. LOG’s portfolio meets this need with advanced solutions for solids and liquids, available in sizes from 15 ml to 1500 ml.

About LOG Pharma Primary Packaging

LOG Pharma Primary Packaging has been serving the global pharmaceutical industry for more than 50 years, offering a wide range of standard and customized packaging solutions. The company operates a manufacturing site in Israel and one in Hungary and is part of Perlen Packaging.

For more information and to schedule a meeting at Pharmapack Europe 2025, visit:  https://logpac.com/event/meet-log-at-pharmapack-europe-2026/.

Contact 

Noam Nahari
VP Marketing & Business Development
LOG Pharma Primary Packaging
+972-50-7429429
noam.nahari@logpac.com

Cision View original content:https://www.prnewswire.com/news-releases/log-to-present-eco-sustainable-barrier-packaging-at-pharmapack-europe-2026-302643406.html

SOURCE LOG Pharma Primary Packaging

Opportunità di mercato
Logo 4
Valore 4 (4)
$0.007634
$0.007634$0.007634
+8.13%
USD
Grafico dei prezzi in tempo reale di 4 (4)
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.